ANXA2 and osteosarcoma: In conclusion, our study reveals the mechanism of S100 A16 in osteosarcoma and suggests that targeting the S100 A16/ANXA2/PI3 K/AKT axis could be a feasible strategy for osteosarcoma therapy.